Voyageur Bolsters Board with Financial Expert for US Market Expansion

Voyageur Pharmaceuticals Ltd., a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, has significantly strengthened its leadership team with the appointment of Virginia Alling as an independent director. This strategic move builds on the company's recent board enhancements with Wall Street veterans Jeffrey J. Kraws and Christopher A. Van Buren, positioning Voyageur for accelerated U.S. capital market access and strategic growth. Ms. Alling brings over 30 years of experience in corporate banking, capital markets, and strategic advisory, currently serving as Senior Vice President & Managing Director at PNC Bank where she manages a multi-billion-dollar portfolio of corporate clients. Her extensive background includes previous roles at JPMorgan Chase and Wells Fargo, with expertise spanning M&A, IPOs, ESOPs, leveraged finance, and revenue optimization.

According to CEO Brent Willis, Alling's appointment complements the recent additions of Kraws and Van Buren, creating a formidable leadership team capable of unlocking institutional U.S. investment and streamlining Voyageur's US market entry. The company believes her deep experience in M&A and capital markets will be instrumental in supporting Voyageur's commercialization efforts, including FDA approvals for its barium contrast products and scaling of its Oklahoma iodine operations. This board strengthening initiative underscores Voyageur's commitment to assembling high-caliber leadership with proven Wall Street acumen to facilitate U.S. market expansion and ensure robust governance as the company scales its innovative barium and iodine pipeline for North American healthcare providers.

Voyageur's ambitious vision centers on becoming the first vertically integrated company in the radiology contrast media drug market, controlling all primary input costs from raw material sourcing to final production. The company owns the Frances Creek barium sulphate project, which features rare, exceptional grade mineral suitable for pharmaceutical applications that Voyageur believes will replace current synthetic products with higher quality imaging alternatives. With its strategic focus on vertical integration and partnerships with established third-party GMP pharmaceutical manufacturers, Voyageur aims to generate sales while transitioning into a high-margin domestic manufacturer of radiology drugs, embodying its motto "From the Earth to the Bottle" through responsible sourcing and manufacturing practices.